Sarah Bowden

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. Epirubicin 74%
3. Adjuvant Chemotherapy 67%
4. Cyclophosphamide 64%
5. SARS Virus 58%
6. Adaptive Clinical Trials 52%
7. Fluorouracil 50%
8. Radiotherapy 43%
9. Actinic Keratosis 39%
10. Oropharyngeal Neoplasms 39%
11. Methotrexate 38%
12. Severe Acute Respiratory Syndrome 38%
13. Coronavirus 37%
14. Drug Therapy 37%
15. Squamous Cell Carcinoma 36%
16. Transplant Recipients 36%
17. Papillomaviridae 36%
18. Medical Overuse 36%
19. Carcinoma, Intraductal, Noninfiltrating 35%
20. C-Reactive Protein 34%
21. gemcitabine 32%
22. Oncologists 32%
23. Anthracyclines 31%
24. Immune System Diseases 31%
25. Feasibility Studies 30%
26. Paclitaxel 29%
27. Folic Acid 29%
28. Therapeutics 28%
29. Workforce 28%
30. Quality of Life 28%
31. Arm 26%
32. Exercise 24%
33. Transplants 24%
34. Recurrence 24%
35. Vaccination 23%
36. X Ray Computed Tomography 23%
37. Clinical Trials 23%
38. Immunomodulation 22%
39. Appointments and Schedules 22%
40. Smoking 21%
41. Health Status 21%
42. Chemoradiotherapy 21%
43. Surgeons 21%
44. Research Ethics Committees 20%
45. Placebos 20%
46. Disease-Free Survival 20%
47. Costs and Cost Analysis 18%
48. Survival 17%
49. Reverse Transcription 17%
50. Publications 16%